Can-Fite BioPharma Ltd.
CANF
$0.53
-$0.04-6.81%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -36.08% | -36.08% | 15.48% | -19.39% | -18.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.08% | -36.08% | 15.48% | -19.39% | -18.73% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -36.08% | -36.08% | 15.48% | -19.39% | -18.73% |
| SG&A Expenses | 35.48% | 35.48% | 5.40% | 22.20% | -9.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.65% | 15.65% | 10.46% | 11.36% | -26.16% |
| Operating Income | -19.64% | -19.64% | -10.03% | -14.74% | 26.70% |
| Income Before Tax | -23.22% | -23.22% | -18.73% | -18.47% | 25.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.22% | -23.22% | -18.73% | -18.47% | 25.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.22% | -23.22% | -18.73% | -18.47% | 25.62% |
| EBIT | -19.64% | -19.64% | -10.03% | -14.74% | 26.70% |
| EBITDA | -19.11% | -19.11% | -10.09% | -14.97% | 26.73% |
| EPS Basic | 36.36% | 36.36% | 27.27% | 21.43% | 50.00% |
| Normalized Basic EPS | 42.86% | 42.86% | 28.57% | 22.22% | 51.28% |
| EPS Diluted | 36.36% | 36.36% | 27.27% | 21.43% | 50.00% |
| Normalized Diluted EPS | 42.86% | 42.86% | 28.57% | 22.22% | 51.28% |
| Average Basic Shares Outstanding | 87.33% | 87.33% | 70.53% | 48.64% | 48.93% |
| Average Diluted Shares Outstanding | 87.33% | 87.33% | 70.53% | 48.64% | 48.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |